Co-encapsulation of Doxorubicin with galactoxyloglucan nanoparticles for intracellular tumor-targeted delivery in murine ascites and solid tumors
Authors: Suraj K George
S Mini
T T Sreelekha
Raveendran K Pillai
S R Aravind
Manu M Joseph
Journal: Translational Oncology (2014)
Discipline: CLINICAL MEDICINE
Keywords: Doxorubicin; Galactoxyloglucan polysaccharide; Nanoparticles; Cancer cells; Cytotoxicity
Affiliations: Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre, Trivandrum, Kerala, India., Department of Hematopathology, UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA., Department of Pathology, Regional Cancer Centre, Trivandrum, Kerala, India., Department of Biochemistry, University of Kerala, Trivandrum, Kerala, India.

Abstract:  Doxorubicin (Dox) treatment is limited by severe toxicity and frequent episodes of treatment failure. To minimize adverse events and improve drug delivery efficiently and specifically in cancer cells, encapsulation of Dox with naturally obtained galactoxyloglucan polysaccharide (PST001), isolated from Tamarindus indica was attempted. Thus formed PST-Dox nanoparticles induced apoptosis and exhibited significant cytotoxicity in murine ascites cell lines, Dalton's lymphoma ascites and Ehrlich's ascites carcinoma. The mechanism contributing to the augmented cytotoxicity of nanoconjugates at lower doses was validated by measuring the Dox intracellular uptake in human colon, leukemic and breast cancer cell lines. PST-Dox nanoparticles showed rapid internalization of Dox into cancer cells within a short period of incubation. Further, in vivo efficacy was tested in comparison to the parent counterparts - PST001 and Dox, in ascites and solid tumor syngraft mice models. Treatment of ascites tumors with PST-Dox nanoparticles significantly reduced the tumor volume, viable tumor cell count, and increased survival and percentage life span in the early, established and prophylactic phases of the disease. Administration of nanoparticles through intratumoral route delivered more robust antitumor response than the intraperitoneal route in solid malignancies. Thus, the results indicate that PST-Dox nanoparticles have greater potential compared to the Dox as targeted drug delivery nanocarriers for loco regional cancer chemotherapy applications. 

Retracted: No

PubPeer comments:
 The images in the two publications are exactly the same; however, the conditions were different. Could the authors clarify this? ![file] , 
 1. The images are duplicated in another publication with a change in magnification. 2. The red highlighted area is reused in the same figure with other conditions. Could the authors clarify this? ![file] , 
 Could the authors clarify this too? ![file] , 
 #1 We found an image error with Figure 2 c d of bright field and fluorescence images of DLA and EAC suspension cells. Theimage was duplicated and was replicated from our previously published paper in the journal Colloids and Surfaces B: Biointerfaces (2014) 116, 219u2013 227). We havenu2019t noticed this error till date and will be happy to rectify the mistake which have occurred. While manuscript preparation we are using previous template for the next manuscript and hence I thought this error happened. We have the actual data with us. This is an error and we have contacted the journal Translational oncology with the new set of images. We will update with the journal response , 
 #1 We found an image error with Figure 2 d of DLA and EAC suspension cells. The same image was replicated from our previously published paper in the journal Colloids and Surfaces B: Biointerfaces (2014) 116, 219u2013 227). We havenu2019t noticed this error till date and will be happy if you can help us to rectify the mistake which have occurred. We have the actual data with us and hence will change the figure in the journal through proper channel. We will update in a couple of weeks , 
 #5 Can you clarify on this erratum which was later retracted. https: pubpeer.com publications DD301A29F43C9CE29224F27E4A9E0A , 
 Nice to hear that you communicated to the journals. The clarification for #1 is applicable; however, it is not for #2 and #3. Because the cropped and magnified images were used in #2 and #3. , 
 The paper has a corrigendum now. Available at https: pubmed.ncbi.nlm.nih.gov 33451514 ,